Based on promising results from plenty of clinical trials, the T-DM1 has been approved for second-line HER2-positive metastatic breast cancer treatment and therapy for HER2-positive early-stage breast cancer with residual cancer following neoadjuvant taxane and trastuzumab [33]. Here, ERBB2 is linked to breast cancer.